Zirabev FDA Approval History
Last updated by Judith Stewart, BPharm on April 10, 2022.
FDA Approved: Yes (First approved June 27, 2019)
Brand name: Zirabev
Generic name: bevacizumab-bvzr
Dosage form: Injection
Company: Pfizer Inc.
Treatment for: Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Zirabev (bevacizumab-bvzr) is a vascular endothelial growth factor (VEGF) inhibitor biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer including metastatic colorectal cancer; non-small cell lung cancer; glioblastoma; metastatic renal cell carcinoma; cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Zirabev (bevacizumab-bvzr) is the the second FDA-approved bevacizumab biosimilar, following the approval of Mvasi (bevacizumab-awwb) in September 2017.
Development timeline for Zirabev
| Date | Article |
|---|---|
| Jun 28, 2019 | Approval FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
